Heide / Schmittel / Kaiser Controversies in the Treatment of Lung Cancer

12th International Symposium on Special Aspects of Radiotherapy, Berlin, October 2008.
1. Auflage 2009
ISBN: 978-3-8055-9299-4
Verlag: S. Karger
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, Band 42, 219 Seiten

Reihe: Frontiers of Radiation Therapy and Oncology

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

Autoren/Hrsg.

Heide, J.

Schmittel, A.

Kaiser, D.

Hinkelbein, W.

Weitere Mitwirkende

Meyer, J.L.

Hinkelbein, W.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Radiologie, Bildgebende Verfahren
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Chirurgie Herz- & Thoraxchirurgie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Pneumologie, Atmung, Asthma
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Chemotherapie

Inhaltsverzeichnis

1;Cover;1
2;Contents;6
3;Prognostic Factors in Histopathology ofLung Cancer;8
3.1;Abstract;8
3.2;Tumor Size: An Essential Prognostic Factor in Lung Cancer;10
3.3;Small Cell Lung Cancer;10
3.4;Prognosis and Predictive Factors in Small Cell Lung Cancer;11
3.5;Histological Subtype: A Prognostic Factor in NSCLC;12
3.6;Squamous Cell Carcinoma Histological Subtypes Associated with Poor Prognosis;12
3.7;Adenocarcinoma Histological Subtypes Associated with Poor Prognosis;13
3.8;Bronchioloalveolar Cell Carcinoma Growth Pattern: A Favorable Prognostic Factor;13
3.9;Large Cell Carcinomas;14
3.10;Prognostic Implication of Molecular Markers;15
3.11;Conclusion;19
3.12;References;20
4;FDG-PET/CT in Lung Cancer: An Update;22
4.1;Abstract;22
4.2;Non-Small Cell Lung Cancer;23
4.3;Staging of Lung Cancer – Distant Metastases;32
4.4;Prediction and Monitoring Response to Therapy;40
4.5;Pleural Metastases;42
4.6;Cost-Effectiveness;43
4.7;Small Cell Lung Cancer;44
4.8;References;44
5;Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer;53
5.1;Abstract;53
5.2;Technical Aspects of Whole-Body MRI;54
5.3;Staging of Lung Cancer Using Whole-Body MRI;54
5.4;Conclusions;60
5.5;References;60
6;Bronchoscopy/Endobronchial Ultrasound;62
6.1;Abstract;62
6.2;EBUS-TBNA: Technique;63
6.3;Clinical Results;65
6.4;Complications;67
6.5;Conclusion;67
6.6;References;68
7;New Developments in Videomediastinoscopy: Video-Assisted Mediastinoscopic Lymphadenectomy and Mediastinoscopic Ultrasound;70
7.1;Abstract;70
7.2;Methods;71
7.3;Results;71
7.4;Comments;74
7.5;Implications for Clinical Practice and Further Research;76
7.6;References;77
8;Resection in Stage I/II Non-Small Cell Lung Cancer;78
8.1;Abstract;78
8.2;Surgery in Stages I and II;79
8.3;Conclusion;82
8.4;References;82
9;Role of Mediastinal Lymph Node Dissection in Non-Small Cell Lung Cancer;85
9.1;Abstract;85
9.2;Surgical Technique of Systematic Lymph Node Dissection;86
9.3;Role of Nodal Involvement on Survival;88
9.4;Impact of Mediastinal Lymph Node Dissection on Operative Morbidity, Mortality and Quality of Life;88
9.5;Diagnostic Role of Mediastinal Lymph Node Dissection;89
9.6;Therapeutic Role of Mediastinal Lymph Node Dissection;90
9.7;Conclusion;91
9.8;References;91
10;Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer;94
10.1;Abstract;94
10.2;Radiation Therapy alone in Early Non-Small Cell Lung Cancer;95
10.3;Avenues for an Improvement of RT Alone in Early NSCLC;98
10.4;References;99
11;Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer;101
11.1;Abstract;101
11.2;Definitions of Stereotactic Body Radiation Therapy;102
11.3;Staging Procedures before SBRT;104
11.4;Implementation of Techniques in Clinical Routine;105
11.5;Biological Basis of Hypofractionated SBRT;108
11.6;Historical Aspects and Early Clinical Experience in SBRT of Lung Cancer;109
11.7;Clinical Experience;109
11.8;Follow-Up Recommendations;116
11.9;Future;117
11.10;References;117
12;Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer;122
12.1;Abstract;122
12.2;Discussion of Stage-Related Treatment;123
12.3;Conclusions;127
12.4;References;127
13;Stage III: Definitive Chemoradiotherapy;129
13.1;Abstract;129
13.2;Optimization of Combined Radiotherapy and Chemotherapy;130
13.3;Which Chemotherapy and Radiotherapy Regimens Are Optimal for Concurrent Chemoradiotherapy?;133
13.4;How Do Comorbidities Influence the Performance of Concurrent Chemoradiotherapy?;137
13.5;References;139
14;Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer;142
14.1;Abstract;142
14.2;Landmark Studies Concerning Adjuvant Platinum-Based Chemotherapy;143
14.3;Negative Studies;144
14.4;The LACE (Lung Adjuvant Cisplatin Evaluation) Meta-Analysis (table 2);144
14.5;Adjuvant Chemotherapy and Stage (table 3);145
14.6;Which Chemotherapy Combination?;147
14.7;Adjuvant Radiotherapy;147
14.8;Patient Selection and Predictive or Prognostic Factors;147
14.9;Neoadjuvant Chemotherapy;149
14.10;Conclusion;149
14.11;References;150
15;Postoperative Irradiation in Non-Small Cell Lung Cancer;152
15.1;Abstract;152
15.2;References;155
16;Altered Fractionation Schemes in Radiotherapy;157
16.1;Abstract;157
16.2;Hypofractionated Stereotactic Body Radiotherapy for NSCLC (Stage I);158
16.3;Hyperfractionated Accelerated Radiotherapy for Stage III NSCLC;161
16.4;References;162
17;Chemotherapy of Advanced Non-Small Cell Lung Cancer;164
17.1;Abstract;164
17.2;Pemetrexed;165
17.3;Cisplatin- vs. Carboplatin-Based Chemotherapy;165
17.4;Elderly Patients and Patients with Reduced Performance Status;166
17.5;Customized Chemotherapy;166
17.6;Targeted Therapies;167
17.7;Maintenance Therapy;167
17.8;Systemic Chemotherapy in Patients Progressing after First-Line Chemotherapy;168
17.9;Assessment of Efficacy;168
17.10;References;169
18;Radiotherapy;171
18.1;Abstract;171
18.2;Clinical Manifestations of Advanced Lung Carcinoma;171
18.3;Palliative Potential of Radiotherapy;172
18.4;Treatment Strategies;174
18.5;References;178
19;Treatment of Limited Disease Small Cell Lung Cancer;180
19.1;Abstract;180
19.2;Thoracic Radiotherapy;181
19.3;Patient Selection;184
19.4;Future Perspectives;185
19.5;References;185
20;Radiochemotherapy in Extensive Disease Small Cell Lung Cancer ED-SCLC;187
20.1;Abstract;187
20.2;RT in ED-SCLC Trial;188
20.3;Future Approaches;191
20.4;Conclusions;192
20.5;References;192
21;Radiotherapy for Extensive Stage Small Cell Lung Cancer;194
21.1;Abstract;194
21.2;Introduction;194
21.3;Brain Metastases;195
21.4;Prophylactic Cranial Irradiation;195
21.5;Thoracic Radiotherapy;197
21.6;References;198
22;Controversies in the Treatment of Advanced Stages of Small Cell Lung Cancer;200
22.1;Abstract;200
22.2;First-Line Chemotherapy;200
22.3;Prophylactic Cranial Irradiation after First-Line Chemotherapy;202
22.4;Second-Line Chemotherapy;202
22.5;References;203
23;Complementary and Alternative Medicinein Lung Cancer Patients: A Neglected Phenomenon?;205
23.1;Abstract;205
23.2;Methods;207
23.3;Results;208
23.4;Discussion;209
23.5;Conclusions;210
23.6;References;211
24;Author Index;213
25;Subject Index;214
26;Back cover;219